SEC Form 4 · accession 0001203311-18-000101

SEATTLE GENETICS INC /WA · SGEN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Clay B Siegall

Officer — President and CEO · Director

Period of report

Dec 10, 2018

Accepted (ET)

Dec 12, 2018 · 7:31 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001060736

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Dec 10, 2018	M	6,300	$12.16	A	738,913	D
Common Stock^F3,F1	Dec 10, 2018	S	6,300	$59.15	D	732,613	D
Common Stock^F1	Dec 10, 2018	M	13,148	$12.16	A	745,761	D
Common Stock^F4,F1	Dec 10, 2018	S	13,148	$59.96	D	732,613	D
Common Stock^F1	Dec 10, 2018	M	700	$12.16	A	733,313	D
Common Stock^F5,F1	Dec 10, 2018	S	700	$60.78	D	732,613	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F6	$12.16	Dec 10, 2018	M	6,300	D	—	Aug 25, 2019	Common Stock	6,300	175,033	D
Non-Qualified Stock Option (right to buy)^F6	$12.16	Dec 10, 2018	M	13,148	D	—	Aug 25, 2019	Common Stock	13,148	161,885	D
Non-Qualified Stock Option (right to buy)^F6	$12.16	Dec 10, 2018	M	700	D	—	Aug 25, 2019	Common Stock	700	161,185	D

Explanation of responses

F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3Reflects sales of common stock executed in multiple transactions at prices ranging from $58.61 to $59.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4Reflects sales of common stock executed in multiple transactions at prices ranging from $59.63 to $60.58. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5Reflects sales of common stock executed in multiple transactions at prices ranging from $60.64 to $60.84. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6Shares vested at a rate of 25% on 8/25/10 and monthly thereafter until all the shares were fully vested on 8/25/13.